You have read all your free articles, to continue reading subscribe to read the rest of this content.
The patent forms the basis of a new vaccine platform that the company has developed in parallel with existing platforms. The company has received a Notice of Allowance of its patent application “Fusion polypeptides comprising one or more inclusion body tags, methods and uses” by the US PatentAlready a subscriber…
Novo Nordisk and UBE Industries have announced that Novo Nordisk has obtained an exclusive worldwide licence to UBE’s preclinical asset UD-014, a selective Semicarbazide-Sensitive Amine Oxidase/Vascular Adhesion Protein-1 (SSAO/VAP-1) inhibitor small molecule, which has shown promising efficacy inAlready a subscriber Login You have read all your free articles, to continue…
Calliditas Therapeutics has announced positive topline results from Part A of the global Phase 3 clinical trial NefIgArd, which investigated the effect of Nefecon versus placebo in patients with primary IgA nephropathy (IgAN). The trial met its primary objective of demonstrating a statistically sAlready a subscriber Login You have read…
Novo Nordisk has entered into a definitive agreement to acquire Dicerna Pharmaceuticals (Dicerna) for a total equity value of approximately USD 3.3 billion. The acquisition of Dicerna’s ribonucleic acid interference (RNAi) platform is a strategic addition to Novo Nordisk’s existing research tAlready a subscriber Login You have read all your…
